Assessing cannabis consumption frequency: Is the combined use of free and glucuronidated THCCOOH blood levels of diagnostic utility? by Hädener, Marianne et al.
1 
 
Drug Testing and Analysis DOI 10.1002/dta.2114 
 
Assessing cannabis consumption frequency: Is the combined use of free and 
glucuronidated THCCOOH blood levels of diagnostic utility? 
 
Authors: 
Marianne Hädener
1
, Marie Martin Fabritius
1
, Stefan König
1
, Christian Giroud
2
, Wolfgang 
Weinmann
1
 
 
 
1 
Affiliation and Address: 
Institute of Forensic Medicine 
University of Bern 
Bühlstrasse 20 
3012 Bern 
Switzerland 
 
 
2 
Affiliation and Address: 
Forensic Toxicology and Chemistry Unit 
University Center of Legal Medicine  
Chemin de la Vulliette 4 
1000 Lausanne 25 
Switzerland 
 
 
Corresponding author:  
Marianne Hädener 
Institute of Forensic Medicine 
University of Bern 
Bühlstrasse 20 
3012 Bern 
Switzerland 
E-mail address: marianne.haedener@irm.unibe.ch 
Telephone number with country code: +41 (0)31 631 30 54 
Fax number with country code: +41 (0)31 631 85 80 
 
 
2 
 
Abstract  
Heavy cannabis consumption is considered incompatible with safe driving. In Swiss traffic 
policy, drivers suspected of regular cannabis use are therefore required to undergo medical 
assessment of their long-term fitness to drive. A whole blood concentration of the cannabis 
metabolite 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) of 40 μg/L is currently used 
by Swiss forensic experts as decision limit for regular cannabis consumption.  The present study 
aimed to investigate the suitability of THCCOOH-glucuronide blood levels as an additional 
and/or better marker for the frequency of cannabis use. Whole blood samples collected from 23 
heavy (≥ 10 joints/month) and 25 occasional smokers (≥ 1 joint/month, but ≤ 1 joint/week) 
enrolled in a placebo-controlled cannabis smoking study were analyzed for THCCOOH and 
THCCOOH-glucuronide. Based on ROC curve analysis concentration thresholds could be 
established for distinguishing between these two groups. Proposed thresholds for heavy use were 
THCCOOH-glucuronide > 52 μg/L (100% specificity; 41% sensitivity) and/or total THCCOOH 
> 58 μg/L (100% specificity; 43% sensitivity). Optimum thresholds for occasional use were 
THCCOOH-glucuronide < 5 μg/L (73% specificity; 97% sensitivity) and/or total THCCOOH < 5 
μg/L (62% specificity; 98% sensitivity). Our results indicate that the THCCOOH-glucuronide 
whole blood concentration is a useful parameter that complements the free THCCOOH level to 
assess the frequency of cannabis consumption. The consideration of the blood concentrations of 
both free and glucuronidated THCCOOH improves the identification of heavy users whose 
fitness to drive has to be carefully assessed. 
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Introduction  
Drug-impaired driving poses a serious threat to global road safety.
[1, 2]
 Driving under the 
influence of cannabis (DUIC) is of particular concern, since cannabis is the most widely abused 
illicit drug worldwide
[3]
 and is clearly the most frequently encountered illicit drug in the blood of 
impaired and fatally injured drivers.
[4-10]
 Numerous studies have investigated the effects of 
cannabis on short and long-term driving performance, as published in a recent review article.
[11]
 
Epidemiologic data show that the risk of being involved in a motor vehicle accident 
approximately doubles after cannabis consumption. Experimental studies, using cognitive and 
psychomotor tests, driving simulators as well as driving tests on closed courses and the open 
road, have confirmed that cannabis adversely affects cognitive functions and psychomotor skills 
required for safe driving (e.g. attention, reaction time, perception, motor skills). These findings 
clearly underline the need for effective laws and legal regulations to address the issue of DUIC. 
Switzerland, among several other European countries,
[12]
 has adopted a zero tolerance policy 
toward DUIC wherein any amount of psychoactive Δ9-tetrahydrocannabinol (THC) in blood 
above the analytical detection limit of 1.5 μg/L is deemed proof of the driver’s acute impairment 
and inability to drive. Legal consequences of DUIC include suspension of the driver’s license for 
several months, a fine, procedural costs, and usually a medical assessment of the long-term 
fitness to drive. Since chronic cannabis consumption suggests an issue of drug addiction, drivers 
suspected of regular cannabis use are required to undergo medical assessment of their fitness to 
drive, even if no THC was detected in their blood.
[13]
 According to the Swiss Road Traffic Act 
drug dependence is incompatible with safe driving and disqualifies a person from holding or 
obtaining a driver’s license.[14] If the medical assessment confirms cannabis dependence and 
unfitness to drive, the driver faces a suspension of the driver’s license for an indefinite period of 
time and must undergo outpatient drug abuse treatment. The driver’s license may be reinstated 
after proving twelve months’ abstinence by regular urine and/or blood samples. Occasional 
cannabis consumption, on the other hand, is not considered to affect the long-term fitness to 
drive. As long as occasional users do not drive under the acute influence of cannabis, they do not 
represent a severe risk to road safety. In Swiss traffic policy, a reliable distinction between 
occasional and heavy cannabis users is thus mandatory within the context of assessing fitness to 
drive. 
Due to its long elimination half-life,
[15]
 11-nor-9-carboxy-THC (THCCOOH), a major phase I 
metabolite of THC, accumulates in the blood upon frequent use.
[16-20]
 Fabritius et al.
[21]
 recently 
showed that THCCOOH blood levels below 3 μg/L are correlated with an occasional use (≥ 1 
joint/month, but ≤ 1 joint/week), whereas concentrations higher than 40 μg/L are indicative of 
heavy consumption (≥ 10 joints/month). Upon the recommendation of the Swiss Society of Legal 
Medicine,
[13]
 this threshold of 40 μg/L is currently used by Swiss forensic experts to classify 
suspected impaired drivers as regular cannabis users whose fitness to drive has to be carefully 
assessed. On the basis of the definitions used by Fabritius et al.,
[21]
 the Swiss Society of Legal 
Medicine agreed on defining occasional cannabis use as “up to twice a week” and regular use as 
“more than twice a week”.[13] The use of THCCOOH blood levels as indicator for the cannabis 
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consumption frequency has also been advocated in Germany
[22]
 and France.
[23]
 However, at the 
moment there is no international agreement, neither on the proposed cutoff concentrations, nor on 
the definition of occasional, regular and heavy cannabis use.
[24]
   
In the study performed by Fabritius et al.,
[21] 
84% of the heavy smokers’ blood samples had 
THCCOOH ≤ 40 µg/L, implying that the cutoff’s sensitivity to detect heavy users is rather low. 
Furthermore, THCCOOH blood levels lying between 3 and 40 μg/L did not allow for a clear 
conclusion regarding the frequency of cannabis use. We assume that this rather modest diagnostic 
performance of the THCCOOH blood concentration to discriminate between occasional and 
heavy cannabis use can be attributed to the fact that THCCOOH undergoes extensive phase II 
metabolism based on its conjugation with glucuronic acid.
[15, 25]
 In several controlled THC 
administration studies, when considering the same time point, the ratio of glucuronidated to free 
THCCOOH in plasma or whole blood showed a high variability across participants,
[16, 20, 25, 26] 
suggesting that interindividual differences in the glucuronidation and elimination rate are 
prominent. Therefore, the THCCOOH blood level is not only determined by the consumption 
frequency, but also depends on the glucuronidation efficiency and kinetics. Sample collection, 
storage and processing conditions are other important factors influencing the amount of free 
THCCOOH since THCCOOH-glucuronide has limited stability and is prone to deconjugation.
[27-
31]
 As reported for THCCOOH,
[16-18, 20]
 plasma, serum and whole blood concentrations of 
THCCOOH-glucuronide were higher in heavy cannabis users than in occasional smokers.
[16, 18, 20]
 
Based on these findings, we hypothesize that THCCOOH-glucuronide blood concentration is a 
valuable supplemental marker for assessing the frequency of cannabis consumption and that the 
combined use of THCCOOH and THCCOOH-glucuronide blood levels, while retaining 
maximum specificity, will increase the diagnostic sensitivity for the detection of regular cannabis 
users. To test this hypothesis, we recently developed a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method for the rapid and simultaneous quantification of THCCOOH 
and THCCOOH-glucuronide in blood.
[32]
 
In the present work, we measured THCCOOH and THCCOOH-glucuronide concentrations in 
blood samples collected from 23 heavy and 25 occasional smokers during a placebo-controlled 
cannabis smoking study. Using receiver operating characteristic (ROC) curve analysis, we 
attempted to determine the best decision threshold concentrations for THCCOOH-glucuronide 
and total THCCOOH for discriminating between occasional and heavy use. 
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Experimental 
Study design and blood collection 
The present work is based on a previously published placebo-controlled cannabis smoking study 
which comprised various neuroimaging and psychomotor investigations, along with toxicological 
analyses of whole blood and oral fluid samples.
[21, 33-35]
 The study’s objectives and procedures 
were reviewed and approved by the Cantonal Research Ethics Committee (Canton of Vaud). 
Subjects provided written informed consent and received financial compensation for their 
participation. The overall study design has been detailed by Battistella et al.
[33]
 and is briefly 
described below. 
The final study population for the toxicological investigations included 23 heavy smokers and 25 
occasional smokers (healthy males, ages 18 – 30 years) who met the following criteria: self-
reported average frequency of cannabis consumption of at least one joint per month and at most 
one joint per week (occasional smokers) or at least ten joints per month (heavy smokers) during 
the three months prior to the study. Very heavy cannabis smokers (> 3 joints/day) were excluded 
from the study, as they were considered unable to abstain from cannabis smoking during the all-
day experimental sessions, particularly during the placebo session. Subjects consuming any 
illegal drug other than cannabis were also disqualified from participation. Subjects were 
requested to abstain from smoking cannabis and tobacco for at least 12 hours prior to the 
experimental days. 
The study comprised two independent cross-over experimental sessions, separated by one week 
in which participants smoked either a cigarette of pure cannabis (0.7 g Bedrobinol, 11% THC, < 
1% CBD) or a placebo (0.8 g Santhica variety, no THC, < 0.1% CBD) according to a fixed-paced 
puffing procedure. The smoked amount of THC averaged about 42 mg. Whole blood samples 
were taken during the screening visit, on admission (5 h before smoking), a few minutes (t = 0 h) 
before inhalation, and 0.2, 0.3, 0.4, 0.65, 1.9, 2.5, and 3.5 h after the start of smoking (actual 
times of blood sampling varied slightly among participants). For occasional smokers, 
experimental sessions should last no more than 3 h after inhalation, thus making the collection of 
the last blood sample impossible. Blood samples were collected in S-monovette
® 
tubes (Sarstedt, 
Sevelen, Switzerland) containing EDTA/fluoride as anticoagulant and enzyme inhibitor and were 
stored at -80 °C before and after analysis.  
 
Determination of blood cannabinoid concentrations 
Whole blood THCCOOH concentrations were measured within a few days after blood collection 
by GC- or LC-MS/MS as described by Fabritius et al.
[21]
 For the present study, the occasional 
and heavy smokers’ blood samples were thawed after storage at -80 °C and were re-analyzed by a 
recently developed LC-MS/MS method for rapid and simultaneous quantification of free and 
glucuronidated THCCOOH.
[32]
 Briefly, 100 µL of whole blood samples were aliquoted into 96 
well-plates and proteins were precipitated by adding 300 µL of cold acetonitrile containing the 
two deuterated internal standards. After mixing and centrifugation, 40 μL of the supernatant were 
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directly injected onto the LC-MS/MS instrument. Linearity ranged from 5 – 500 µg/L for both 
analytes [the lowest calibrator being the lower limit of quantification (LLOQ)]. THCCOOH 
concentrations measured in the present study showed little deviation (median: 2.1%) from the 
concentrations determined shortly after blood sampling by Fabritius et al.
[21]
 and therefore prove 
stability of the blood samples for the time period between sampling and re-analysis. 
 
Data analysis  
Data were analyzed using Microsoft Excel 2010 and GraphPad Prism 6.05 softwares for 
Windows. Unless otherwise specified, all data points were employed in statistical analyses, 
including estimates below the LLOQ and non-detectable concentrations. The latter ones were set 
to zero. Pharmacokinetic parameters, including highest observed concentrations (Cmax) after 
smoking, time at Cmax (tmax), concentrations at each time point, and glucuronide/free THCCOOH 
ratios were compared between occasional and heavy smokers by use of the Mann–Whitney exact 
test. Significance was attributed at two-tailed P < 0.05. Receiver operating characteristic (ROC) 
curve analysis was performed to determine optimal cutoff values to discriminate between heavy 
and occasional smokers. True positives (TP) were correctly classified smokers, i.e. heavy 
smokers with cannabinoid concentrations higher than the cutoff. False positives (FP) were 
incorrectly identified heavy smokers, i.e. occasional smokers with cannabinoid concentrations 
higher than the cutoff. True negatives (TN) were correctly rejected smokers, i.e. occasional 
smokers with cannabinoid concentrations lower than the threshold. False negatives (FN) were 
incorrectly rejected smokers, i.e. heavy smokers with cannabinoid levels lower than the 
threshold. Sensitivity (true heavy rate) and specificity (true occasional rate) were defined by the 
ratios TP/(TP + FN) and TN/(TN + FP), respectively. The overall ability of the cannabinoid 
blood level as diagnostic marker to discriminate between occasional and heavy smokers was 
evaluated by the area under the ROC curve (AUC). An AUC value close to 1 indicates an 
excellent discriminatory power, whereas a ROC curve coinciding with the diagonal (AUC = 0.5) 
suggests no discrimination.
[36] 
Total THCCOOH concentration was determined by converting the 
sum of molar THCCOOH and THCCOOH-glucuronide concentrations into the mass 
concentration of free THCCOOH equivalents. The LLOQ of total THCCOOH was derived from 
the LLOQ of THCCOOH-glucuronide and was calculated to be 3.3 µg/L (5 µg/L of THCCOOH-
glucuronide is 9.6 nmol/L which corresponds to 3.3 µg/L of free THCCOOH equivalents). 
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Results and discussion 
Study participants 
Twenty-three heavy and 25 occasional smokers, all men, participated in the study. Demographic 
characteristics and self-reported histories of cannabis use are detailed in Tables S1 and S2 (see 
supporting information). The two user groups were very similar with regard to the age on 
admission, body mass index, age at first cannabis use as well as the lifetime years smoked, but 
they clearly differed in their self-reported frequency of use. Heavy smokers consumed on 
[median (range)] 20.0 (5 – 60) occasions per week during the three weeks preceding the study, 
whereas occasional smokers smoked 3.5 (< 1 – 8) times per month during the three months 
preceding the study. Joints were generally shared with 2.5 (0 – 4) persons among heavy smokers 
and with 3.5 (2 – 5) persons among occasional smokers. Considering this, all subjects included in 
the group of occasional users smoked one joint or less per week. 
 
Kinetic profiles and pharmacokinetic parameters of THCCOOH and THCCOOH-glucuronide  
Median time profiles of THCCOOH and THCCOOH-glucuronide concentrations of heavy and 
occasional smokers, before and after smoking of a cannabis or placebo cigarette are presented in 
Figure 1. The kinetic profile of THCCOOH has been previously discussed in detail by Fabritius 
et al.
[21]
 THCCOOH-glucuronide concentrations were highly variable among participants, 
although they smoked the same amount of cannabis, which is likely due to prior cannabis 
experience (different smoking habits and inhalation techniques). Despite these wide 
interindividual variations, median THCCOOH-glucuronide concentrations were found to be 
markedly higher in frequent smokers compared to occasional smokers at all time points, as 
observed by Desrosiers et al.
[20]
 In the group of heavy smokers median THCCOOH-glucuronide 
concentrations were higher than free THCCOOH concentrations throughout the experiment 
timeframe. Conjugated THCCOOH levels decreased from [median (range)] 59.2 µg/L (10.5 – 
336.0 µg/L) to 50.8 µg/L (7.9 – 275.0 µg/L) before smoking the cannabis cigarette and slightly 
increased thereafter, reaching a maximum of 59.7 µg/L (20.8 – 358.0 µg/L) within 2.0 h (0.3 - 
3.5 h) post-smoking, as indicated in Table 1. Several occasional smokers had undetectable 
THCCOOH-glucuronide blood levels on admission, resulting in a median of zero µg/L prior to 
smoking. Glucuronide levels gradually increased post-smoking and remained elevated for the 
remainder of the experiment reaching a maximum of 15.9 µg/L (< LLOQ – 47.3 µg/L) within 2.6 
h (1.5 - 2.9 h). At the end of the experiment timeframe THCCOOH-glucuronide concentrations 
exceeded those of free THCCOOH. 
To our knowledge, only two studies have documented THCCOOH-glucuronide concentrations in 
whole blood following controlled cannabis smoking. Whereas in the study by Schwope et al.
[25]
 
only chronic frequent smokers were recruited, Desrosiers et al.
[20]
 compared THCCOOH-
glucuronide pharmacokinetics in occasional and frequent smokers. In both studies, participants 
smoked a single 6.8% THC (total amount: 54 mg THC) cigarette ad libitum over 10 min and 
cannabinoid blood concentrations were monitored for up to 22 h and 30 h, respectively, after 
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smoking. For the heavy smokers they reported median (range) THCCOOH-glucuronide Cmax of 
89 µg/L (46 – 220 µg/L)[25] and 74.3 µg/L (40.4 – 218 µg/L)[20], respectively. For the occasional 
smokers Cmax was 16.2 µg/L (0 – 83.4 µg/L).
[20] 
In contrast to our study Schwope et al.
[25]
 and 
Desrosiers et al.
[20]
 included very heavy cannabis smokers with a self-reported average cannabis 
use ≥ 3 joints/day (median was 5.5 joints/day and 4.5 joints/day, respectively). For the occasional 
users the self-reported average consumption frequency should not exceed 1 time/week in our 
study, whereas Desrosiers et al.
[20]
 restricted it to up to 2 times/week. In our view, the lower 
median THCCOOH-glucuronide Cmax values observed in this study are likely a consequence of 
the lower self-reported cannabis intake of our participants in the months preceding the 
experiment, resulting in lower THCCOOH-glucuronide baseline levels. 
We also determined cannabinoid levels before and after smoking the placebo cigarette (Table 1). 
The majority of the occasional users’ blood samples were free of THCCOOH-glucuronide during 
placebo conditions, resulting in median values of zero μg/L for all time points. In the heavy users, 
THCCOOH-glucuronide was detectable in all samples within a range of < LLOQ – 191.0 μg/L. 
Median (range) concentrations decreased from 41.5 µg/L (< LLOQ – 191.0 µg/L) to 32.7 µg/L (< 
LLOQ – 119.0 µg/L) between 5 h before and 3 h after smoking the placebo cigarette. 
The blood sampling period of only 3.5 h after smoking was considered too short for reliable 
determination of the elimination half-life. Kelly et al.
[16]
 calculated in heavy users a terminal 
plasma THCCOOH–glucuronide elimination half-life of 6.8 ± 4.5 d, and of 3.7 ± 2.0 d in 
occasional users based on an observation time period of 12 d after intravenous THC 
administration. For THCCOOH they found terminal elimination half-lives of 5.2 ± 0.8 d and 6.2 
± 6.7 d, respectively. Glaz-Sandberg et al.
[37]
 observed a terminal serum THCCOOH elimination 
half-life of 17.6 ± 5.5 h in healthy, drug-free men, when monitoring THCCOOH concentrations 
up to 96 h after intravenous THCCOOH administration. Due to its high lipophilicity THC is 
rapidly and extensively distributed into adipose tissue,
[38, 39]
 from where it is slowly released back 
into the bloodstream and metabolized.
[40, 41]
 This, as well as significant enterohepatic 
recirculation,
[42-45]
 are the main reasons for the long terminal elimination half-lives and the 
prolonged detection times of THCCOOH and THCCOOH-glucuronide in blood. Regular 
cannabis use over an extended timeframe creates a heavy burden of cannabinoids in the body, 
which was illustrated by the high THCCOOH-glucuronide baseline concentrations in the group 
of heavy smokers as observed in our study, by Schwope et al.
[25]
 and also by Desrosiers et al.
[20]
 
 
Glucuronide/free THCCOOH ratios  
We calculated glucuronide to free THCCOOH ratios based on molar concentrations before and 
after smoking of the cannabis cigarette (Figure 1). Ratios across time ranged from 0.15 – 4.99 
(median 1.17) in heavy users and from 0.05 – 2.65 (median 0.49) in occasional users. Differences 
in ratios between the two user groups were significant (P < 0.0001) at any time point after 
smoking. Ratios before smoking could only be reported for three occasional smokers since the 
other participants had undetectable THCCOOH and/or THCCOOH-glucuronide blood levels.   
In both user groups, THCCOOH concentrations increased more rapidly than THCCOOH-
glucuronide concentrations post-smoking, leading to a brief decrease of the median 
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glucuronide/free THCCOOH ratios immediately following smoking. As time passes, free 
THCCOOH underwent UGT-catalyzed glucuronidation
[46]
 and thus the ratios slowly increased, 
approaching baseline levels. This trend was previously reported by Schwope et al.
[25]
 and 
Desrosiers et al.
[20] 
In agreement with their studies, we observed a high variability between 
participants at a given time point. In contrast to our findings, Desrosiers et al.
[20]
 observed higher 
ratios in occasional than in heavy users. However, they found no significant differences. 
Schwope et al.
[25]
 reported ratios ranging from 0.43 to 5.3 (median 2.05) across participants and 
time of sampling and Desrosiers et al.
[20]
 observed ratios > 5 on several occasions. These higher 
ratios were mainly found at time points exceeding our observation period (> 3.5 h), i.e. during the 
late elimination phase. 
Within the 5 h prior to smoking, the median ratio in the group of heavy smokers increased, 
suggesting gradual glucuronidation of free THCCOOH. Since participants were admitted to the 
research unit only approximately 5 h before cannabis administration, some of the heavy smokers 
were possibly still intoxicated at the first time of cannabis dosing and were therefore in an early 
elimination phase.  
 
Concentration differences for THCCOOH-glucuronide and total THCCOOH between occasional 
and heavy cannabis smokers 
Concentrations of THCCOOH-glucuronide and total THCCOOH (sum of free and glucuronide) 
were found to be significantly higher in the group of heavy smokers than in occasional users (P < 
0.0001) at any time point of the two experimental sessions as well as during the initial screening 
visit. The results of the Mann-Whitney test are summarized in Table 1. The differences between 
the two groups for THCCOOH-glucuronide tmax were not significant, which is in agreement with 
the observations made by Desrosiers et al.
[20]
 
A significant difference was also found when comparing the distribution of THCCOOH-
glucuronide and total THCCOOH blood levels between the two groups over the entire 
experiment timeframe, including the concentrations of the cannabis and placebo sessions and 
those measured during the screening visit (Figure 2). In the occasional users’ blood samples the 
glucuronide concentrations ranged from 0 - 51.6 µg/L, whereas for the heavy smokers the range 
was < LLOQ - 358.0 µg/L. Total THCCOOH concentrations ranged from 0 - 57.9 µg/L in the 
occasional users and from 3.4 - 377.3 µg/L in the heavy users. 
Figure 2 reveals that there was a considerable overlap in the concentration ranges of the two 
groups of participants. This is due to the fact that Cmax values determined in the blood of 
occasional users were not significantly different from those measured in heavy smokers before 
smoking the cannabis cigarette or during the placebo session (Table 1). 
 
Determination of cutoff concentrations and optimal decision thresholds by ROC curve analysis  
Receiver operating characteristic (ROC) curve analyses were conducted to establish cutoff values 
and optimal decision threshold concentrations to discriminate between heavy and occasional 
smokers. Figure 3 presents the ROC curves obtained with all the THCCOOH-glucuronide and 
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total THCCOOH concentrations measured throughout the study, including those of the placebo 
session and screening visit (n = 840). The occasional smokers were considered as control group, 
whereas the group of heavy smokers was defined as study group. The ROC curve is a plot of true 
positive rate (sensitivity) versus false positive rate (1-specificity) for different cutoff points. Thus, 
each point on the ROC curve represents a sensitivity/1-specificity pair associated with a 
particular discrimination threshold. The overall ability of the cannabinoid blood levels as 
diagnostic markers to discriminate between occasional and heavy smokers was evaluated by the 
area under the ROC curve (AUC). AUC was 0.96 and 0.94, respectively, thus indicating that 
THCCOOH-glucuronide and total THCCOOH blood levels have a high discriminatory power for 
the recognition of heavy use, as previously hypothesized. 
The best decision threshold should combine high sensitivity and maximum specificity. The 
choice of this decision limit is necessarily a sensitivity/specificity tradeoff: lowering the cutoff 
value to increase sensitivity will decrease specificity and vice versa. The appropriate balance 
between the two depends on the intended use of the diagnostic indicator. For our forensic 
purposes, high specificity is required to avoid a false accusation of chronic cannabis use. 
Therefore, the specificity for the identification of heavy smokers was set to 100% (false positive 
rate = 0; y-axis of the ROC-curve) and the cutoff was chosen to maximize sensitivity. 
Specificities of 100% were obtained for cutoff concentrations higher than the observed maxima 
for occasional users’, i.e. for THCOOH-glucuronide and total THCCOOH concentrations higher 
than 51.6 µg/L and 57.9 µg/L, respectively (Figure 2). So we propose the following two blood 
concentration decision thresholds for discriminating heavy from occasional users: 52 µg/L of 
THCCOOH-glucuronide and 58 µg/L of total THCCOOH. ROC-curve analysis revealed that 
these thresholds are correlated with sensitivities of 41% and 43%, respectively (Figure 3, circle 
1). Thus, 59% and 57% of the heavy users’ samples had blood levels < 52 µg/L of THCCOOH-
glucuronide and < 58 µg/L of total THCCOOH, respectively.  
In a similar way as Fabritius et al.,
[21]
 we also tried to establish a decision limit that can be used 
to rule out heavy smokers. For this purpose, we determined the threshold that showed the closest 
sensitivity to 100% and was associated with the highest specificity (Figure 3, circle 2). For both 
the THCCOOH-glucuronide and total THCCOOH blood level the optimal threshold to rule out 
heavy users was found to be 5 µg/L. Specificities were 73% and 62%, respectively, and 
sensitivities were 97% and 98%, respectively. The diagnostic characteristics of the proposed 
decision thresholds to discriminate between occasional and heavy use are summarized in Table 2. 
Compared to the previously established threshold of 40 µg/L for free THCCOOH,
[21]
 these new 
decision limits for THCCOOH-glucuronide and total THCCOOH blood concentrations offer 
much better sensitivities (Table 2). Thus, as stated in our working hypothesis, the use of these 
decision thresholds significantly improves the sensitivity of the detection of heavy users, 
however, with the constraint of measuring the concentrations of free THCCOOH and 
THCCOOH-glucuronide separately or together after hydrolysis.  
Regarding the identification of occasional users (i.e. exclusion of heavy users), the decision limits 
assessed with blood THCCOOH-glucuronide and total THCCOOH ROC curves resulted in no 
appreciable improvement of the test performance compared to the criteria previously determined 
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with the free THCCOOH blood concentration. In our study, 27% of the occasional smokers’ 
blood samples had THCCOOH-glucuronide levels higher than the proposed limit of 5 µg/L. For 
the total THCCOOH threshold, the proportion was 38%. As observed before with free 
THCCOOH blood thresholds,
[21]
 there was a gray zone of THCCOOH-glucuronide and total 
THCCOOH concentrations which could not be reliably interpreted. This suggests that 
THCCOOH-glucuronide or total THCCOOH concentrations measured several hours to days after 
smoking can hardly be used to assess the frequency of cannabis use and to distinguish heavy 
from occasional cannabis smoking. 
 
Application of the proposed decision limits 
According to Swiss traffic policies, driving and cannabis consumption should be strictly 
separated. The more often a person consumes cannabis, the more likely he/she is to drive under 
the acute influence of cannabis. Compared to occasional users, regular users are assumed to be 
less able to separate cannabis consumption from driving. Since the ability to separate between 
cannabis consumption and driving is an important prerequisite for the fitness to drive, a medical 
assessment is required when regular cannabis use is suspected. The Swiss Society of Legal 
Medicine
[13] 
recommends that a THCCOOH blood concentration of 40 μg/L or higher should be 
considered as an indication for regular cannabis consumption, as proposed by Fabritius et al.,
[21]
 
and decided to define regular cannabis consumption as ”more than twice a week” which is in 
agreement with the self-reported average frequency of cannabis use of the heavy smokers 
included in the study by Fabritius et al.
[21]
 (≥ 10 joints/month, i.e. ≥ 2.3 joints/week). At the 
moment, no international consensus on the definition of occasional, regular and heavy cannabis 
use exists.
[24]
  
In the study conducted by Fabritius et al.
[21]
 the currently used THCCOOH threshold of 40 μg/L 
showed a sensitivity of only 16% for heavy cannabis use. Therefore, with the current procedure 
only a small percentage of the heavy cannabis users in Switzerland are correctly identified and 
referred for medical assessment of the fitness to drive. Since the proposed decision limits for 
THCCOOH-glucuronide and total THCCOOH are correlated with better sensitivities, they 
improve the detection of heavy users and are expected to result in a higher number of unfit 
drivers being prohibited from driving. In order to give a quantitative estimate of this 
improvement in Swiss forensic practice, we applied the newly proposed decision limits for heavy 
cannabis use to actual 926 suspected DUI cases. The drivers’ whole blood specimens were 
submitted to our institute for routine analysis of THC, 11-OH-THC and THCCOOH by an 
established LC-MS/MS method.
[30]
 All drivers considered for this evaluation had detectable 
THCCOOH levels (≥ 2.5 µg/L), which identified them as cannabis consumers. To determine 
THCCOOH-glucuronide and total THCCOOH concentrations, the blood samples were re-
analyzed with our recently developed LC-MS/MS method.
[32]
 
About 50% (n = 469) of the drivers tested positive for THC in blood (≥ 2.2 µg/L). This THC 
positivity threshold corresponds to the Swiss analytical cutoff of 1.5 µg/L plus a confidence 
interval of 30% (i.e. 2.2 µg/L minus 30% is 1.54 which is just higher than the analytical cutoff of 
1.5 µg/L). Due to the Swiss zero tolerance policy for DUIC, these THC positive cases were 
12 
 
reported to the administrative authorities and were referred for medical assessment of the long-
term fitness to drive, irrespective of whether they were presumed to be heavy or occasional users. 
Thus, the impact of the proposed cutoff values in practice is better demonstrated with drivers who 
tested negative for THC (< 2.2 µg/L).  
Only 2% of the 457 THC negative drivers were suspected of heavy cannabis use by applying the 
previously established decision cutoff for free THCCOOH (≥ 40 µg/L). Taking into account our 
newly proposed decision limits for total THCCOOH blood level (≥ 58 µg/L), an additional 18% 
of the drivers would be classified as heavy users and therefore need to undergo medical 
assessment of their fitness to drive. When applying the proposed threshold for the THCCOOH-
glucuronide blood level (≥ 52 µg/L), this would be 23%. If medical assessment confirms heavy 
cannabis use and unfitness to drive, a considerable number of unfit drivers would be detected and 
prohibited from driving, which would be a clear benefit for road safety.  
Another point in favor of using the newly proposed decision limits is the instability of 
THCCOOH-glucuronide. Under certain sample transport, storage and processing conditions, 
substantial deconjugation of THCCOOH-glucuronide can occur, leading to erroneously elevated 
blood concentrations of free THCCOOH 
[27-31]
, drivers being falsely classified as heavy users and 
drivers being classified differently by different laboratories since (pre-)analytical procedures can 
vary among laboratories. Therefore, taking into account the concentrations of both free and 
glucuronidated THCCOOH, either by measuring free THCCOOH and THCCOOH-glucuronide 
separately or together after hydrolysis, is highly advisable for a reliable assessment of the 
cannabis consumption frequency. 
We are aware, that the validity and usefulness of the proposed decision limits used in the context 
of forensic practice need further evaluation and confirmation with more traffic offenders’ cases. 
 
Strengths and limitations of the study design 
The study design ensured that a wide range of conditions encountered in forensic practice were 
taken into account. Samples collected during the placebo session presented blood concentrations 
typically found in the late elimination phase, whereas blood samples taken during the first 3 h 
following cannabis smoking reflected concentrations of the distribution and early elimination 
phase. Furthermore, two methods of administration were considered. Blood levels measured 
during the screening visit or during the placebo session resulted from ad libitum self-
administration, whereas blood levels determined after cannabis smoking were produced by 
controlled paced smoking. Consequently, we conclude that our study provides appropriate and 
reliable data for establishing decision limit concentrations to discriminate between occasional and 
heavy cannabis use. A limitation of the study is the short observation time period after smoking, 
which was due to the fact that experimental sessions had to be restricted to one day.
[21] 
If the 
blood sampling period had been longer, a higher number of lower concentrations would have 
been measured, thus lowering the sensitivities of the proposed decision limits for heavy cannabis 
use. The inclusion of very heavy cannabis users (> 3 joints/day), on the other hand, would 
probably have improved sensitivity. Another limitation is that the study included only male 
participants and there might be differences in sex due to the higher body fat percentage in 
13 
 
women
[47]
 and accumulation of cannabinoids in adipose tissue.
[38, 39]
 Additional research is on-
going to determine the validity of the proposed cutoffs for female smokers and under further 
conditions such as different dosages, other administration routes (oral ingestion, vaporization) 
and simultaneous consumption of alcohol or other drugs that may interact with cannabis kinetics 
and effects. 
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Conclusions 
We evaluated the diagnostic value of THCCOOH-glucuronide and total THCCOOH 
concentrations in blood as criteria to distinguish heavy from occasional smokers. Based on ROC 
curve analysis, two decision limits were proposed: a THCCOOH-glucuronide blood level higher 
than 52 µg/L was found to be indicative of heavy use, whereas a concentration lower than 5 µg/L 
was correlated with occasional cannabis consumption. Regarding the total THCCOOH blood 
level we suggest 58 µg/L and 5 µg/L as thresholds for heavy and occasional consumption, 
respectively. 
Since heavy cannabis consumption may cause long-term driving impairment, a medical 
assessment of the fitness to drive is compulsory in Switzerland for drivers suspected of heavy 
cannabis misuse. Diagnostic tools for the classification of impaired drivers as heavy or occasional 
users are thus important. In our opinion, the aforementioned decision limits could help to detect 
unfit drivers because of heavy cannabis use. To benefit from these new diagnostic tools, the 
separate determination of THCCOOH and THCCOOH-glucuronide or of total THCCOOH in 
blood should become more common in forensic practice. 
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Tables 
 
Table 1. Median (range) pharmacokinetic group comparison of THCCOOH-glucuronide and 
total THCCOOH in whole blood of heavy and occasional users before and after smoking 
Analyte and  
parameter 
Heavy  
smokers  
(n = 23) 
Occasional  
smokers  
(n = 25) 
Mann-Whitney  
U 
P 
      Cannabis condition 
   
THCCOOH-glucuronide
a
 
   
 
C-5h (µg/L) 59.2 (10.5 - 336.0) 0 (0 - 31.9) 9 < 0.0001 
 
C0 (µg/L) 50.8 (7.9 - 275.0) 0 (0 - 20.5) 8 < 0.0001 
 
Cmax (µg/L) 59.7 (20.8 - 358.0) 15.9 (< 5 - 47.3) 17 < 0.0001 
 
tmax (h) 2.0 (0.3 - 3.5) 2.6 (1.5 - 2.9) 256.5 0.5289 
 
C2.5h (µg/L) 59.2 (18.6 - 316.0) 15.1 (< 5 - 47.3) 17.5 < 0.0001 
      
THCCOOH total
b
  
    
 
C-5h (µg/L) 69.7 (10.9 - 377.3) 0 (0 - 32.7) 10 < 0.0001 
 
C0 (µg/L) 60.5 (8.1 - 279.4) 0 (0 - 20.5) 9 < 0.0001 
 
Cmax (µg/L) 81.0 (25.1 - 344.9) 20.6 (< 3.3 - 48.5) 13 < 0.0001 
 
tmax (h) 0.4 (0.2 - 3.5) 1.7 (0.3 - 2.8) 149 0.0037 
 
C2.5h (µg/L) 66.5 (20.2 - 289.0) 17.5 (< 3.3 - 48.0) 25 < 0.0001 
      Placebo condition 
   THCCOOH-glucuronidea 
   
 
C-5h (µg/L) 41.5 (< 5 - 191.0) 0 (0 - 51.5) 16 < 0.0001 
 
C0 (µg/L) 33.1 (< 5 - 152.0) 0 (0 - 40.5) 27 < 0.0001 
 
C2.5h (µg/L) 32.7 (< 5 - 119.0) 0 (0 - 33.9) 24 < 0.0001 
      THCCOOH totalb  
    
 
C-5h (µg/L) 47.8 (3.9 - 269.4) 0 (0 - 57.9) 15 < 0.0001 
 
C0 (µg/L) 32.9 (4.9 - 168.6) 0 (0 - 48.2) 25 < 0.0001 
  C2.5h (µg/L) 31.4 (3.5 - 150.9) 0 (0 - 42.5) 27.5 < 0.0001 
a 
LLOQ was 5 µg/L 
b
 LLOQ was 3.3 µg/L 
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Table 2. Diagnostic characteristics of THCCOOH, THCCOOH-glucuronide and total 
THCCOOH concentrations thresholds 
 Analyte Blood level (µg/L) Sensitivity (%) Specificity (%) 
Heavy smokers rule out thresholds   
 THCCOOH free 
a 
< 3 97 62 
 THCCOOH-glucuronide < 5 97 73 
 THCCOOH total < 5 98 62 
     
Heavy smokers rule in thresholds   
 THCCOOH free 
a 
> 40 16 100 
 THCCOOH-glucuronide > 52 41 100 
 THCCOOH total > 58 43 100 
a 
Data reported by Fabritius et al.
[21] 
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Figures 
 
Figure 1. Median (interquartile) time profiles of a THCCOOH, b THCCOOH-glucuronide, and c 
molar THCCOOH-glucuronide-to-THCCOOH ratios in whole blood of 25 occasional and 23 
heavy users before and after smoking of a cannabis cigarette. Dotted lines indicate limits of 
quantification (5 µg/L each) and n values indicate data points for occasional users’ ratios (for 
heavy users, n = 23 at all times). 
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Figure 2. Scatter plot (median and interquartile) comparing the distribution of THCCOOH-
glucuronide and total THCCOOH concentrations in whole blood samples of occasional and 
heavy users measured throughout the study (occasional: n = 418; heavy: n = 422). Dotted lines 
indicate occasional users’ maximum concentrations (51.6 and 57.9 µg/L, respectively). Mann-
Whitney test revealed significant differences between occasional and heavy users’ blood levels 
(two-tailed P < 0.0001). 
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Figure 3. ROC curves of a THCCOOH-glucuronide and b total THCCOOH concentrations in 
whole blood samples measured throughout the study (n = 840). Circle 1 = threshold to rule in 
heavy users (52 µg/L and 58 µg/L, respectively), Circle 2 = threshold to rule out heavy users (5 
µg/L each).
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Supporting Information 
Table S1.  Demographic characteristics, self-reported histories of cannabis use and measured cannabinoid concentrations for 23 heavy 
smokers 
 
THCCOOH 
free 
THCCOOH-
glucuronide
THCCOOH
 total 
THCCOOH 
free 
THCCOOH-
glucuronide
THCCOOH
 total 
THCCOOH 
free 
THCCOOH-
glucuronide
THCCOOH
 total 
1 Ea 21 23,2 15 6 5 e e e < LLOQ - 31.2 16.1 - 47.9 16.6 - 51.6 9.7 - 24.4 22.5 - 35.0 24.6 - 47.6
2 E/AF 22 22,1 14 8 14 e e e 43.0 - 83.9 84.9 - 106.0 109.8 - 142.1 24.5 - 34.4 45.2 - 68.2 54.6 - 79.5
3 E 20 19,0 16 4 5 20,2 56,4 57,5 10.1 - 31.1 38.9 - 66.9 37.3 - 62.3 12.8 - 31.0 49.5 - 81.6 48.1 - 85.0
4 E 20 20,0 16 4 20 e e e 20.4 - 50.1 61.3 - 87.2 61.0 - 91.3 10.6 - 17.8 31.7 - 45.6 33.8 - 48.0
5 AF 22 22,8 19 3 16 e e e 6.2 - 25.5 23.7 - 49.0 24.3 - 51.8 6.0 - 9.7 23.3 - 32.1 22.1 - 31.0
6 E 22 22,5 19 3 20 9,2 25,7 26,2 5.1 - 25.0 18.8 - 39.8 17.6 - 41.0 < LLOQ 8.1 - 12.8 8.1 - 12.6
7 E 25 23,0 12 13 20 97,4 227,0 247,6 79.9 - 155.0 275.0 - 358.0 279.4 - 377.3 e e e
8 E 19 21,8 15 4 60c < LLOQ 19,6 15,8 8.5 - 23.3 26.5 - 45.6 27.6 - 46.9 7.2 - 16.7 26.8 - 38.9 26.1 - 42.4
9 AF 27 22,7 19 8 20 27,6 50,4 60,9 19.2 - 37.7 39.5 - 54.3 51.7 - 66.4 7.9 - 16.0 20.6 - 31.6 22.6 - 36.9
10 E 24 18,9 15 9 42c 63,0 124,0 145,0 38.5 - 88.3 115.0 - 153.0 120.6 - 189.5 21.8 - 42.1 58.2 - 92.6 60.7 - 93.6
11 E 25 21,8 15 10 50c 164,0 220,0 309,6 80.4 - 154.0 139.0 - 173.0 181.1 - 256.6 54.9 - 143 119 - 191 145.1 - 269.4
12 E 21 21,4 18 3 18 35,3 76,2 85,7 26.9 - 67.1 33.3 - 62.5 60.5 - 98.5 21.5 - 42.3 58.5 - 132.0 63.0 - 129.6
13 E 22 21,1 14 8 25c 10,4 31,0 30,9 5.3 - 30.5 21.5 - 47.5 19.6 - 53.6 5.4 - 16.5 22.3 - 36.3 21.0 - 40.5
14 E 24 26,1 20 4 10 19,5 54,9 55,8 10.5 - 34.4 66.4 - 79.2 55.3 - 80.2 < LLOQ - 7.1 27.0 - 37.5 23.3 - 31.9
15 E/AS 20 21,6 12 8 28c 17,7 38,8 43,4 40.2 - 86.6 69.2 - 103.0 86.0 - 136.4 21.0 - 36.9 44.6 - 71.1 55.3 - 76.3
16 E 25 22,3 19 6 6 12,5 37,7 37,4 6.8 - 30.7 18.9 - 33.4 23.4 - 49.2 2.6 - 6.5 8.0 - 11.3 9.2 -13.8
17 E 23 21,4 15 8 30c 30,4 115,0 106,5 23.1 - 76.5 94.4 - 170.0 86.2 - 189.0 21.4 - 51.0 111.0 - 166.0 96.2 - 160.8
18 E 25 20,4 20 5 25c 61,8 121,0 141,9 31.2 - 53.0 53.0 - 59.2 66.7 - 91.3 17.5 - 29.3 39.3 - 55.0 45.6 - 65.7
19 E 22 18,1 15 7 14 44,3 134,0 133,0 35.1 - 62.2 76.4 - 99.8 91.4 - 123.0 13 - 29.1 44.9 - 57.6 46.2 - 65.6
20 E 24 26,4 15 9 16 22,6 57,8 60,8 < LLOQ - 11.7 7.4 - 20.8 8.1 - 25.1 < LLOQ < LLOQ 3.4 - 4.9
21 E 20 20,4 16 4 15 19,8 25,2 36,5 7.2 - 53.0 11.5 - 28.5 14.8 - 62.7 0 - 7.5 < LLOQ - 7.4 4.1 - 12.3
22 E 23 18,0 15 8 25c 16,0 31,7 37,0 29.2 - 48.2 49.8 - 77.2 63.8 - 82.7 5.6 - 14.5 20.0 - 35.5 21.3 - 37.0
23 E 24 21,8 15 9 12 < LLOQ 8,4 8,2 27.8 - 49.0 46.6 - 55.6 61.7 - 81.0 19.8 - 32.9 38.7 - 44.1 46.5 - 61.8
Mean 22,6 21,6 16,0 6,6 21,6
SD 2,1 2,1 2,3 2,7 13,7
Median 22,0 21,8 15,0 7,0 20,0
c Self-reported average use at screening was < 3 joints/day.
d Range of concentrations measured on admission (5 h before smoking), a few minutes before inhalation, and 0.2, 0.3, 0.4, 0.65, 1.9, 2.5, and 3.5 h after the start of smoking. 
e Not measured due to lack of sample material for re-analysis.
during cannabis sessiond during placebo sessiond
Cannabinoid concentrations (µg/L)
Ethnicity
Age on 
admission
Body 
mass 
indexb
Age 
at first 
useb
Lifetime 
years 
smokedb
Frequency of useb 
(times/week, 
last three weeks) 
Participant
a E, European; AF, African; AS, Asian.
b Data collected on admission.
 at screening visit 
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Table S2. Demographic characteristics, self-reported histories of cannabis use and measured cannabinoid concentrations for 25 
occasional smokers 
 
THCCOOH 
free 
THCCOOH-
glucuronide
THCCOOH
 total 
THCCOOH 
free 
THCCOOH-
glucuronide
THCCOOH
 total 
THCCOOH 
free 
THCCOOH-
glucuronide
THCCOOH
 total 
1 Ea 23 25,5 13 10 2 0 0 0 0 - 6.2 0 - 5.9 0 - 7.9 0 0 0
2 E 24 24,4 9 15 4 0 0 0 0 - 8.9 0 - 14.4 0 - 16.1 0 0 - < LLOQ 0 - < LLOQ
3 AS 26 22,4 23 4 2 0 0 0 0 - 14.9 0 - 13.3 0 - 19.0 0 0 - < LLOQ 0 - < LLOQ
4 E 25 21,8 14 11 1 0 0 0 0 - 11.0 0 - 11.3 0 - 12.5 0 0 - < LLOQ 0 - < LLOQ
5 E 26 21,2 18 8 1 0 0 0 0 - 18.8 0 - 14.9 0 - 20.9 0 0 0
6 E 28 18,8 18 10 2 0 0 0 0 - 11.5 0 - 6.4 0 - 12.7 0 0 0
7 E 26 21,9 20 6 4 0 0 0 0 - 15.1 0 - 16.8 0 - 22.0 0 0 - < LLOQ 0 - < LLOQ
8 E 26 18,0 14 12 8c 0 0 0 0 - 20.0 < LLOQ - 32.1 < LLOQ - 33.0 0 < LLOQ < LLOQ
9 E 27 18,5 17 10 5c < LLOQ < LLOQ 4,2 0 - 21.8 < LLOQ - 32.6 < LLOQ - 39.5 0 0 0
10 E 24 22,1 17 7 5c 0 0 0 0 - 12.9 < LLOQ - 28.6 < LLOQ - 28.9 0 < LLOQ < LLOQ
11 E 19 20,3 13 6 4 0 0 0 0 - 25.6 0 - 18.6 0 - 28.4 0 0 - < LLOQ 0 - < LLOQ
12 E 25 24,2 21 4 6c 0 0 0 0 - 12.3 0 - 17.1 0 - 20.2 0 0 - < LLOQ 0 - < LLOQ
13 E 19 22,9 15 4 4 < LLOQ < LLOQ 4,2 0 - 16.6 < LLOQ - 18.5 < LLOQ - 25.4 < LLOQ < LLOQ 3.4 - 4.8
14 E 27 21,6 19 8 5c 0 6,9 4,5 7.3 - 32.2 12.5 - 23.9 15.6 - 48.0 0 8.2 - 10.6 5.4 - 7.0
15 E 24 25,7 18 6 2 0 0 0 0 - 14.2 0 - 15.9 0 - 17.8 0 0 0
16 E 20 23,5 14 6 1 g g g 0 - 0 0 - 2.6 0 - 1.7 0 0 0
17 E/AF 29 29,1 18 11 1 < LLOQ < LLOQ 3,9 0 -18.9 0 - 12.0 0 - 20.6 < LLOQ < LLOQ < LLOQ - 4.2
18 E 25 21,5 15 10 8c 0 0 0 0 - 8.8 0 - 4.9 0 - 10.2 0 0 - < LLOQ 0 - < LLOQ
19 E 22 22,0 16 6 < 1d g g g 0 - 0 0 - 3.1 0 - 2.1 0 0 0
20 E 20 22,1 15 5 5c 28,4 42,6 56,5 7.3 - 23.7 13.7 - 39.1 16.4 - 46.5 11.9 - 25.2 32.6 - 38.1 34.9 - 48.2
21 E 20 24,2 16 4 3 0 0 0 0 - 11.0 0 - 15.0 0 - 16.6 0 0 0
22 E 21 27,8 17 4 3 0 0 0 0 - 5.4 0 - 5.8 0 - 8.6 0 0 0
23 E 21 23,5 14 7 2 0 0 0 0 - 12.6 0 - 26.3 0 - 24.0 0 0 0
24 E 22 20,6 18 5 4 0 0 0 0 - 13.9 < LLOQ - 17.6 < LLOQ - 20.8 0 0 - < LLOQ 0 - < LLOQ
25 E 28 19,8 16 12 e < LLOQ < LLOQ 5,6 7.0 - 31.5 18.5 - 47.3 20.5 - 48.5 15.9 - 23.9 33.0 - 51.5 35.6 - 57.9
Mean 23,9 22,5 16,3 7,6 3,5
SD 3,0 2,7 2,9 3,1 2,3
Median 24,0 22,1 16,0 7,0 3,5
c Self-reported average use at screening was ≤ 1 joint/week.
d Self-reported average use at screening was ≥ 1 joint/month.
e Data not collected.
f Range of concentrations measured on admission (5 h before smoking), a few minutes before inhalation, and 0.2, 0.3, 0.4, 0.65, 1.9, and 2.5 h after the start of smoking. 
g Not measured due to lack of sample material for re-analysis.
during placebo sessionf
Cannabinoid concentrations (µg/L)
Lifetime 
years 
smokedb
Frequency of useb 
(times/month, 
last three months) 
Participant Ethnicity
Age on 
admission
Age 
at first 
useb
Body 
mass 
indexb
a E, European; AF, African; AS, Asian.
b Data collected on admission.
at screening visit during cannabis sessionf
